Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 17/20 | 0.85 |
| ▸ | SSTR4 | P31391 | 11/20 | 0.85 |
| ▸ | SSTR5 | P35346 | 12/20 | 0.71 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.71 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30044563 | 0.96 | SSTR2 (0.82) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL29414545 | 0.90 | SSTR2 (0.84) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL30604479 | 0.88 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL30670730 | 0.87 | SSTR2 (0.80) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL21099762 | 0.86 | SSTR2 (0.78) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL29414547 | 0.86 | SSTR4 (0.70) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL21096706 | 0.86 | SSTR2 (0.78) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| SCHEMBL25556872 | 0.85 | SSTR2 (0.76) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| Vapreotide SCHEMBL31632623 | 0.85 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 | |
| Vapreotide SCHEMBL6369050 | 0.85 | SSTR2 (0.81) | SSTR2SSTR4SSTR5SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024100285-A1 | TREATMENT OF A COGNITIVE DISORDER WITH AN AGENT THAT INCREASES THE EXCITABILITY OF THE CLAUSTRUM | UNIVERSITÉ DE GENÈVE (CH) | 2024-05-16 | — | — | WO | claimed |
| CN-116981479-A | FAP-activated radiation therapy diagnostic method and use relating thereto | 塔夫茨大学信托人 | 2023-10-31 | — | — | CN | claimed |
| EP-4262878-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | claimed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-118496992-B | Device and method for islet high-throughput perfusion culture and imaging | 北京大学 | 2025-01-24 | — | — | CN | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| CN-118496992-A | Device and method for islet high-throughput perfusion culture and imaging | 北京大学 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024100285-A1 | TREATMENT OF A COGNITIVE DISORDER WITH AN AGENT THAT INCREASES THE EXCITABILITY OF THE CLAUSTRUM | UNIVERSITÉ DE GENÈVE (CH) | 2024-05-16 | — | — | WO | disclosed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116981479-A | FAP-activated radiation therapy diagnostic method and use relating thereto | 塔夫茨大学信托人 | 2023-10-31 | — | — | CN | disclosed |
| EP-4262878-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | SSTR2 497/4885SSTR4 793/4885SSTR5 1013/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | SSTR2 1877/4885SSTR4 695/4885SSTR5 894/4885 |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | FAP, FIBP, FGFR1 | SSTR2 3666/4885SSTR4 2682/4885SSTR5 3496/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | SSTR2 1012/4885SSTR4 1149/4885SSTR5 975/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | SSTR2 1014/4885SSTR4 2441/4885SSTR5 1568/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | SSTR2 371/4885SSTR4 1088/4885SSTR5 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.